Articles

A longitudinal observational study examined whether the program was related to access to hospital-based services, while determining if that association differs by hospital ownership.

The Association Between 340B Program Involvement and Availability of Hospital Services

The agreement will look to further develop cell and gene therapies for the treatment of hematological cancers.

Charles River, Gates Institute Strike Lentiviral Vector Manufacturing Deal 

A retrospective study investigates whether use of these portals can be defined by clinical and sociodemographic data.

Differences in Patient Portal Engagement Among Hypertension Patients

The Hopewell facility—which will serve as the CDMO’s North American hub—is expected to help accelerate the cell and gene therapy delivery process. 

ProBio Opens New Viral Vector Production Plant in the Garden State

The company acquires Alimera Sciences for $381 million upfront, while establishing its interest in ophthalmology.

ANI Pharmaceuticals Expands Rare Disease Offerings

A study examines the economical validity of using this therapy as a treatment for unresectable stage III non–small cell lung cancer.

Investigating the Cost-Effectiveness of Durvalumab

Videos

In an interview with Pharma Commerce Editor Nicholas Saraceno, Fran Gregory, PharmD, Vice President of Emerging Therapies, Cardinal Health, discusses ways that changes made to reimbursement models are affecting patient therapies in the biosimilar space. 

Making Adjustments to Reimbursement Models Impacting Patient Therapies in the Biosimilar Space

The partnership will offer an end-to-end manufacturing solution for biopharma companies. 

Abzena, Argonaut Form Drug Development Alliance

Podcasts

Mark Bouck discusses PharmAlliance’s latest acquisitions, while reiterating its goals surrounding health economics and outcomes research.

Navigating Market Access Hurdles

The acquisition of the 87,000 square-foot Camden, MD plant provides the CDMO with the ability to offer clinical and commercial non-viral aseptic fill-finish services on four fill lines.

News